Volker Heinemann
福尔克尔·海内曼
MD
Professor of Medicine; Head, Comprehensive Cancer Center Munich医学教授；慕尼黑综合癌症中心主任
👥Biography 个人简介
Volker Heinemann, MD is Professor of Medicine at LMU Munich and Head of the Comprehensive Cancer Center Munich, one of Germany's largest oncology programs. He is a leading European clinical trialist in gastrointestinal and pancreatic cancers, having contributed to the pivotal MPACT trial validating gemcitabine plus nab-paclitaxel in metastatic PDAC, which resulted in a major regulatory approval and global practice change. His group also leads comparative effectiveness research on FOLFIRINOX vs. gemcitabine/nab-paclitaxel and has pioneered the use of molecular profiling to guide therapy selection in advanced pancreatic cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Gemcitabine/nab-Paclitaxel in Metastatic PDAC (MPACT Trial)
Co-investigator on the MPACT phase III trial demonstrating superior overall survival, progression-free survival, and response rate for gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic PDAC, establishing a key new first-line standard alongside FOLFIRINOX.
Comparative Effectiveness of First-Line PDAC Regimens
Led German multicenter registry studies and retrospective analyses comparing outcomes of FOLFIRINOX versus gemcitabine/nab-paclitaxel in real-world practice, informing patient selection and informing treatment individualization strategies.
Neoadjuvant Therapy in Borderline Resectable PDAC
Directed prospective trials evaluating neoadjuvant FOLFIRINOX and gemcitabine-based regimens for locally advanced and borderline resectable PDAC, contributing to evolving paradigms of multimodal treatment.
Representative Works 代表性著作
nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival from a Phase III Trial
Journal of the National Cancer Institute (2015)
Extended follow-up analysis of MPACT confirming durable survival benefit of gemcitabine/nab-paclitaxel, cementing its role as a first-line standard in metastatic PDAC.
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Comparative Cohort Analysis
Annals of Oncology (2020)
Real-world comparative study evaluating recurrence-free survival and tolerability of adjuvant FOLFIRINOX versus gemcitabine-based therapy in resected PDAC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 福尔克尔·海内曼 的研究动态
Follow Volker Heinemann's research updates
留下邮箱，当我们发布与 Volker Heinemann（Ludwig Maximilian University of Munich, University Hospital (LMU Klinikum)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment